

Publication of inside information according to Art. 17 MAR



Management Board and Supervisory Board will propose to the Annual General Meeting an ordinary capital increase

Darmstadt, 29. June 2021 – The Management Board of CytoTools AG (ISIN DE000A0KFRJ1) has decided to convene the Annual General Meeting of the company for 21 July 2021. The Annual General Meeting is to be held virtually. The Management Board and Supervisory Board will propose to the Annual General Meeting, among other things, that an ordinary capital increase be resolved. In accordance with the proposed resolution, the capital stock of the Company is to be increased against cash contributions by issuing up to 805,600 new no-par value bearer shares with dividend rights from January 1, 2021. The shareholders are to be granted subscription rights at a ratio of 5 : 1 (five old shares each grant subscription rights to one new share). The subscription price is to be EUR 9.93 per new share. The proceeds from the issue would be used to promote further product development and to cover the expenses of ongoing business operations. The Supervisory Board approved the convening of the Annual General Meeting today and adopted the proposed resolution.

Contact:

CytoTools AG
Ingo Middelmenne
Investor Relations
Mobile: +49-174-9091190
Email: middelmenne@cytotools.de

-- Supplementary information --

About CytoTools:

CytoTools AG is a German biotechnology holding company that translates results from basic cell biology research on cell growth and programmed cell death into novel therapies for causal disease treatment and cure. CytoTools' versatile product pipeline includes proprietary chemical compounds and biopharmaceuticals that have the potential to provide new treatment options in dermatology, cardiology, urology and oncology. CytoTools is structured as a technology holding and investment company and holds interests in its subsidiaries DermaTools Biotech GmbH (65%) and CytoPharma GmbH (50%).